Sign up

Commodore Capital LP

$1.7B assets · 33 holdings · Q2 2026 · Filed 14 AUG 2026

About Commodore Capital LP’s 13F portfolio

Commodore Capital LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Commodore Capital LP reported $1.7B across 33 US-listed positions (). Its largest position is RELAY THERAPEUTICS INC (RLAY) at 13% of the reported book, and its ten biggest holdings make up 68% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$1.7B
Assets (13F)
#1,680
of 8,839 by size
33
Holdings
68%
Top-10 weight
11
Buys
17
Sells
Top holdings · Q2 2026
33 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: RLAY
RELAY THERAPEUTICS INC
—
—
13%
12.0M$224.5M
2
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
—
—
9.9%
3.3M$166.2M
3
NASDAQ: ALKS
ALKERMES PLC
—
—
9.4%
3.0M$157.2M
4
NASDAQ: COGT
COGENT BIOSCIENCES INC
—
—
7.0%
3.0M$118.0M
5
NASDAQ: AMLX
AMYLYX PHARMACEUTICALS INC
—
—
6.0%
5.7M$101.5M
6
NASDAQ: DFTX
DEFINIUM THERAPEUTICS INC
—
—
5.6%
2.0M$94.1M
7
NASDAQ: SYRE
SPYRE THERAPEUTICS INC
—
—
4.5%
847K$75.2M
8
NYSE: ANRO
ALTO NEUROSCIENCE INC
—
—
4.3%
2.7M$71.9M
9
NASDAQ: TNGX
TANGO THERAPEUTICS INC
—
—
4.2%
2.3M$70.3M
10
NASDAQ: EYPT
EYEPOINT INC
—
—
3.9%
4.6M$65.8M
11
NASDAQ: TYRA
TYRA BIOSCIENCES INC
—
—
3.6%
1.9M$59.9M
12
NASDAQ: DMRA
DAMORA THERAPEUTICS INC
—
—
3.0%
1.9M$50.4M
13
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC NEW
—
—
3.0%
1.4M$50.2M
14
NASDAQ: PHVS
PHARVARIS N V
—
—
2.9%
1.4M$49.3M
15
NASDAQ: LBRX
LB PHARMACEUTICALS INC
—
—
2.9%
1.5M$48.7M
16
NASDAQ: ASMB
ASSEMBLY BIOSCIENCES INC
—
—
2.3%
1.4M$38.9M
17
NASDAQ: EDIT
EDITAS MEDICINE INC
—
—
1.7%
8.9M$28.8M
18
NASDAQ: KYMR
KYMERA THERAPEUTICS INC
—
—
1.7%
250K$28.7M
19
NYSE American: CATX
PERSPECTIVE THERAPEUTICS INC
—
—
1.3%
6.3M$21.6M
20
NASDAQ: IPSC
CENTURY THERAPEUTICS INC
—
—
1.3%
8.7M$21.3M
21
NASDAQ: ZURA
ZURA BIO LTD
—
—
1.1%
3.3M$19.2M
22
NASDAQ: AVTX
AVALO THERAPEUTICS INC
—
—
1.1%
1.0M$18.8M
23
NASDAQ: IFRX
INFLARX NV
—
—
1.0%
7.3M$16.4M
24
NASDAQ: ANTX
AN2 THERAPEUTICS INC
—
—
0.8%
2.9M$14.2M
25
NASDAQ: NUVL
NUVALENT INC
—
—
0.7%
100K$12.3M

Showing 1–25 of 33 positions on this page reported in this 13F.

Sector allocation
  • Healthcare91%
Recent activity · vs 2026-03-31
Bought11
  • AddedCOGTCOGENT BIOSCIENCES INC+5.6%$118.0M
  • NewTNGXTANGO THERAPEUTICS INC—$70.3M
  • AddedEYPTEYEPOINT INC+62.8%$65.8M
  • AddedASMBASSEMBLY BIOSCIENCES INC+41.5%$38.9M
  • NewEDITEDITAS MEDICINE INC—$28.8M
  • AddedAVTXAVALO THERAPEUTICS INC+111%$18.8M
  • NewIFRXINFLARX NV—$16.4M
  • AddedANTXAN2 THERAPEUTICS INC+25.7%$14.2M
  • AddedRLMDRELMADA THERAPEUTICS INC+125%$9.9M
  • NewRACCRESEARCH ALLIANCE CORP III—$5.3M
Sold17
  • ReducedRLAYRELAY THERAPEUTICS INC−29.4%$224.5M
  • ReducedALKSALKERMES PLC−28.6%$157.2M
  • ReducedSYRESPYRE THERAPEUTICS INC−55.7%$75.2M
  • ReducedTYRATYRA BIOSCIENCES INC−24.2%$59.9M
  • ReducedCLDXCELLDEX THERAPEUTICS INC NEW−49.9%$50.2M
  • ReducedPHVSPHARVARIS N V−25.7%$49.3M
  • ReducedKYMRKYMERA THERAPEUTICS INC−66.7%$28.7M
  • ReducedNUVLNUVALENT INC−88.0%$12.3M
  • ReducedSABSSAB BIOTHERAPEUTICS INC−34.8%$11.2M
  • SoldOCULOCULAR THERAPEUTIX INC−100%—
5%+ Beneficial Ownership Stakes · 8 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
CATX
Perspective Therapeutics, Inc.
13G9.9% · 2 classes11.9MFiled 09 FEB 2026
2
SABS
SAB Biotherapeutics, Inc.
13G9.9% · 2 classes8.9MFiled 14 AUG 2026
3
ANTX
AN2 Therapeutics, Inc.
13G9.9%3.9MFiled 16 NOV 2026
4
ANRO
Alto Neuroscience, Inc.
13G9.9% · 2 classes3.6MFiled 15 MAY 2026
5
IPSC
Century Therapeutics, Inc.
13G7.1%13.0MFiled 16 JAN 2026
6
PEPG
PepGen Inc.
13G6.5% · 2 classes4.5MFiled 15 MAY 2026
7
TYRA
Tyra Biosciences, Inc.
13G6.3%3.4MFiled 14 NOV 2025
8
RACC
Research Alliance Corp III
13G5.5%500KFiled 28 MAY 2026

Showing all 8 disclosed stakes.

Reading Commodore Capital LP’s 13F portfolio

Commodore Capital LP’s $1.7B 13F book is spread across 33 reported positions and is highly concentrated — its ten largest positions alone are 68% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RLAY, ELVN, ALKS, COGT and AMLX, led by RELAY THERAPEUTICS INC (RLAY) at 13% of the portfolio. The heaviest sector exposure is Healthcare (91%).

What Commodore Capital LP changed last quarter

Between 2026-03-31 and Q2 2026, Commodore Capital LP was a net seller: it opened 5 new positions and added to 6 more, while trimming 9 and closing 8 outright. Against a 33-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was COGENT BIOSCIENCES INC (COGT), and its biggest reduction was RELAY THERAPEUTICS INC (RLAY).

What a 13F does and doesn’t reveal

A 13F captures only Commodore Capital LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Commodore Capital LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Commodore Capital LP's profile on this page is built directly from those filings.

How current is the 13F data on Commodore Capital LP's page?

It reflects Commodore Capital LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Commodore Capital LP files its next quarterly report, this page refreshes automatically.

Can I see Commodore Capital LP's complete list of holdings?

This page highlights Commodore Capital LP's largest positions rather than all 33 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Commodore Capital LP's filings.

Does a 13F show everything Commodore Capital LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Commodore Capital LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Commodore Capital LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.